SCHEMBL25836728

SCHEMBL25836728

CC(=O)Cn1cc(CC(=O)OC(C)(C)C)nn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.42
MEN1 O00255 1/20 0.39
GLA P06280 1/20 0.39
KMT2A Q03164 1/20 0.39
KDM1A O60341 10/20 0.36
KDM1B Q8NB78 2/20 0.36
TUBB4A P04350 1/20 0.36
TUBB P07437 1/20 0.36
TUBA3C P0DPH7 1/20 0.36
TUBA1B P68363 1/20 0.36
TUBA4A P68366 1/20 0.36
TUBB4B P68371 1/20 0.36
TUBB3 Q13509 1/20 0.36
TUBB2A Q13885 1/20 0.36
TUBB8 Q3ZCM7 1/20 0.36
TUBA3E Q6PEY2 1/20 0.36
TUBA1A Q71U36 1/20 0.36
TUBA1C Q9BQE3 1/20 0.36
TUBB6 Q9BUF5 1/20 0.36
TUBB2B Q9BVA1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23038456 0.90 ALDH1A1 (0.41) ALDH1A1MEN1GLAKMT2AKDM1A
SCHEMBL15257810 0.81 CA1 (0.54) ALDH1A1MEN1GLAKMT2ACA12
SCHEMBL23038547 0.80 CYP1A2 (0.46) ALDH1A1GLAKDM1A
SCHEMBL25836729 0.80 SRC (0.38) ALDH1A1KMT2A
SCHEMBL25014093 0.79 ALDH1A1 (0.42) ALDH1A1MEN1GLAKMT2AKDM1A
SCHEMBL25974297 0.79 MTNR1A (0.39) ALDH1A1KMT2AKDM1AKDM1BCA12
SCHEMBL12673478 0.78 HSP90AB1 (0.43) ALDH1A1MEN1GLAKMT2AKDM1A
SCHEMBL18235987 0.76 POLB (0.38) ALDH1A1GLAKMT2AGGPS1
SCHEMBL15257805 0.74 MAOA (0.43) ALDH1A1KMT2ACA12CA1CA2
SCHEMBL16891850 0.74 POLB (0.38) ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230287009-A1 OXO-SUBSTITUTED COMPOUND Sumitomo Pharma Co., Ltd. (JP) 2023-09-14 US disclosed
US-11702431-B2 Oxo-substituted compound Sumitomo Pharma Co., Ltd. (JP) 2023-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11702431-B2 Oxo-substituted compound CYP51A1, OXA1L, O60361 ALDH1A1 473/4885MEN1 3561/4885GLA 10/4885
US-20230287009-A1 OXO-SUBSTITUTED COMPOUND CYP51A1, OXA1L, O60361 ALDH1A1 473/4885MEN1 3561/4885GLA 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.